Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Non Operating Income (2019 - 2024)

Eton Pharmaceuticals' Non Operating Income history spans 6 years, with the latest figure at -$1.1 million for Q4 2024.

  • For Q4 2024, Non Operating Income fell 7025.0% year-over-year to -$1.1 million; the TTM value through Dec 2024 reached -$1.2 million, down 340.76%, while the annual FY2024 figure was -$1.2 million, 340.76% down from the prior year.
  • Non Operating Income for Q4 2024 was -$1.1 million at Eton Pharmaceuticals, down from -$8000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $676000.0 in Q2 2023 and bottomed at -$1.1 million in Q4 2024.
  • The 5-year median for Non Operating Income is -$171000.0 (2020), against an average of -$149900.0.
  • The largest annual shift saw Non Operating Income soared 410.09% in 2023 before it tumbled 7025.0% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$267000.0 in 2020, then fell by 3.0% to -$275000.0 in 2021, then soared by 45.45% to -$150000.0 in 2022, then skyrocketed by 89.33% to -$16000.0 in 2023, then crashed by 7025.0% to -$1.1 million in 2024.
  • Per Business Quant, the three most recent readings for ETON's Non Operating Income are -$1.1 million (Q4 2024), -$8000.0 (Q3 2024), and -$52000.0 (Q2 2024).